Características
Se ha publicado la convocatoria transnacional conjunta del partenariado ERA4HEALTH, Joint Transnational Call for Investigator-Initiated Clinical Studies (JTC IICS) – 2026 Trials4Health 2026: Multi-country Investigator-Initiated Clinical Trials in Cardiovascular, Autoimmune and Metabolic diseases
Los objetivos de la convocatoria son apoyar estudios clínicos multicéntricos, aleatorizados e iniciados por investigadores, centrados en la efectividad comparada y/o la reutilización de fármacos, con un diseño claramente justificado y transparente. Además, busca fomentar la colaboración transnacional entre equipos clínicos y de salud pública que realicen este tipo de ensayos.
La convocatoria está cofinanciada por la Unión Europea y cuenta con un presupuesto total estimado de más de 35 millones de euros. En ella participa como organismo financiador nacional el Instituto de Salud Carlos III (ISCIII) con un presupuesto de 2.400.000€ para la financiación de 3-4 propuestas.
Requisitos
Proposals should take into account the following points that apply according to the selected clinical trial design:
- The proposed study needs to be a pragmatic comparative effectiveness trial and/or a drug repurposing trial, designed as Phase III randomised interventional trial. The clinical design should be appropriate and justified. Cluster randomisation could be considered in the clinical trial design if justified.
- In case of comparative effectiveness trials, these must compare the use of currently approved or existing healthcare interventions (see definition), used in clinical practice in Europe, either to each other or to the current standard of care.
- In case of comparative effectiveness trials, these must consider existing, approved healthcare interventions(see definition) which could include but would not be limited to: diagnostic, screening, prevention and treatment interventions. The interventions can be pharmacological as well as non-pharmacological procedures like well-defined, reproducible and targeted nutritional and lifestyle interventions, surgery, prognosis methods, use of medical devices, nano and advanced health technologies, eHealth and digital interventions and other health interventions.
- In case of drug repurposing trials,the aim shall be to explore a new indication of an approved off-patent medication. Given that this call is supported by public funding, clinical studies with a commercial purpose are excluded, therefore only off-patent drug repurposing trials are allowed.
- These interventions shall have high public relevance in at least one of these specific diseases or conditions (that are of equal importance):
- Cardiovascular diseases
- Metabolic disorders
- Autoimmune diseases (including antibody-based autoimmune diseases and/or also other Immune-mediated inflammatory diseases.
The focus of the multi-country Investigator-Initiated Clinical Studies is cardiovascular, metabolic or autoimmune disorders as primary causes of illness. Proposals may focus on a single cardiovascular, metabolic or autoimmune disease, or they may explore these conditions in combination with comorbidities.
Beyond the research topics, the requirements and recommendations should be considered (check the Call text for further information).
Plazo de presentación.
En la siguiente table se detallan las diferentes fechas:
| Phase | Date |
|---|---|
| Call opens | November 13, 2025 |
| Deadline pre-proposals | January 27, 2026, (16:00 CET) |
| Submission of invited full proposals | June 17, 2026 (16:00 CET) |